Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Inclusion Criteria:

- Malignant conditions for which CD34+ selected, T-cell depleted allogeneic
hematopoietic stem cell transplantation is indicated such as:

AML in 1st remission - for patients whose AML does not have 'good risk' cytogenetic
features (i.e. t 8;21, t15;17, inv 16).

- Secondary AML in 1st remission

- AML in 1st relapse or > 2nd remission

- ALL/LL in 1st remission clinical or molecular features indicating a high risk for
relapse; or ALL > 2nd remission

- CML failing to respond to or not tolerating Imatinib, dasatinib, or nilotinib in first
chronic phase of disease; or CML in accelerated phase or second chronic phase.

- Non-Hodgkins lymphoma with chemoresponsive disease in any of the following categories:
a) intermediate or high grade lymphomas who have failed to achieve a first CR or have
relapsed following a 1st remission who are not candidates for autologous transplants.

- any NHL in remission which is considered not curable with chemotherapy alone and not
eligible/appropriate for autologous transplant. Myelodysplastic syndrome (MDS):
RA/RCMD with high risk cytogenetic features or transfusion dependence, RAEB-1 and
RAEB-2 and Acute myelogenous leukemia (AML) evolved from MDS, who are not eligible for
transplantation under protocol IRB 08-008.

- Chronic myelomonocytic leukemia: CMML-1 and CMML-2.

- Other rare lethal disorders of Hematopoiesis and Lymphopoiesis for which a T-cell
depleted transplant is indicated (e.g. hemophagocytic lymphohistiocytosis; refractory
aplastic anemia or conjugated cytopenias; non-SCID lethal genetic immunodeficiencies
such as Wiskott Aldrich Syndrome, CD40 ligand deficiency, ALPS).

- Patients may be of either gender and of any racial or ethnic background.

- Patients must have a Karnofsky (adult) or Lansky (pediatric) Performance Status > 70%.

- Patients must have adequate organ function measured by:

Cardiac: asymptomatic or if symptomatic then LVEF at rest must be > 50% and must improve
with exercise.

- Hepatic: < 3x ULN ALT and < 2.0x ULN total serum bilirubin, unless there is congenital
benign hyperbilirubinemia.

- Renal: serum creatinine <1.2 mg/dl or if serum creatinine is outside the normal range,
then CrCl > 40 ml/min (measured or calculated/estimated)

- Pulmonary: asymptomatic or if symptomatic, DLCO > 50% of predicted (corrected for
hemoglobin)

- Each patient must be willing to participate as a research subject and must sign an
informed consent form.

Exclusion Criteria:

- Female patients who are pregnant or breast-feeding

- Uncontrolled viral, bacterial or fungal infection

- Patient seropositive for HIV-I/II; HTLV -I/II

- Presence of leukemia in the CNS.

Donor Inclusion Criteria:

- Each donor must meet criteria outlined by institutional policies

- Donor must have adequate peripheral venous catheter access for leukapheresis or must
agree to placement of a central catheter.

Donor Exclusion Criteria:

- Evidence of active infection (including urinary tract infection, or upper respiratory
tract infection), viral hepatitis exposure (on screening), unless only HBS Ab+ and HBV
DNA negative, or serologic evidence of exposure or infection with HIV-I/II or
HTLV-I/II

- If donors do not meet institutional guidelines, exclusion will be considered.